Redeye: Xvivo Perfusion - Harvest Season is Coming
We have conducted a survey to transplant physicians I the United States and Europe. Results indicate a high potential for warm perfusion. In light of the survey results and a deeper analysis of the newly formed collaboration with United Therapeutics, we forecast a slightly faster adaption of warm perfusion than previously accounted for. Our new fair value (base case) is SEK 160 (110) per share.
Read more and download the research update: http://bit.ly/2w6PmOb
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/